Vorinostat Medication: Uses, Dosage, and Cancer Treatment

Key Points About Vorinostat Medication

Vorinostat is a prescription medication primarily used to treat certain types of cancer, including cutaneous T-cell lymphoma and other blood-related cancers. This drug works by inhibiting specific enzymes that contribute to the growth and survival of cancer cells. Vorinostat is typically taken orally, and it is crucial to follow your doctor’s instructions carefully. Common side effects may include fatigue, nausea, and diarrhea. Always consult your healthcare provider before starting or adjusting your dose. For personalized guidance, consider scheduling a telemedicine visit with us.

Names of Vorinostat Medication

US Brand Name: Zolinza

Generic Name: Vorinostat

The generic name, Vorinostat, refers to the active ingredient in the medication, while Zolinza is the brand name assigned by the manufacturer.

Pharmacologic Category of Vorinostat

Histone Deacetylase (HDAC) Inhibitor

Vorinostat Dosage Guidelines

Vorinostat is prescribed for a variety of cancers, with the dosage tailored to the specific condition being treated. It is essential to follow your doctor’s instructions and avoid changing your dose without medical advice. If you need assistance, our telemedicine team is here to help.

Vorinostat Dosage for Cutaneous T-cell Lymphoma (CTCL)

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Peripheral T-cell Lymphoma

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Hodgkin Lymphoma

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Non-Hodgkin Lymphoma

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Multiple Myeloma

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Acute Myeloid Leukemia (AML)

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Chronic Lymphocytic Leukemia (CLL)

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Myelodysplastic Syndromes

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Solid Tumors

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Vorinostat Dosage for Lymphoproliferative Disorders

1. Recommended Dose: 400 mg once daily
2. Frequency: Daily
3. Length of Treatment: Continue until disease progression or unacceptable side effects occur

Dosage Forms and Strengths of Vorinostat

Capsules: 100 mg

How to Take Vorinostat: Administration Instructions

Vorinostat is taken orally, typically once daily. Swallow the capsules whole with food to minimize the risk of stomach upset. Do not crush, chew, or open the capsules. If you miss a dose, take it as soon as you remember, unless it is close to your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Never take two doses at once. If you have any questions about how to take your medication, consult your healthcare provider or schedule a telemedicine appointment with us.

Contraindications for Vorinostat

A contraindication refers to a condition or circumstance in which a medication, such as Vorinostat, should not be used because it may pose significant risks to the patient. Vorinostat, a histone deacetylase inhibitor commonly used in cancer treatment, has specific contraindications that must be carefully assessed to prioritize patient safety. Below is a detailed overview of these contraindications and the reasons why Vorinostat is not recommended in these situations:

Severe liver disease: Vorinostat is metabolized by the liver. In individuals with severe liver impairment, the drug may build up in the body, increasing the risk of toxicity and serious side effects.

Severe kidney disease: Patients with significant kidney dysfunction may struggle to eliminate Vorinostat from their system effectively, which can heighten the likelihood of adverse reactions.

Known hypersensitivity to Vorinostat: If a patient has previously experienced an allergic reaction to Vorinostat or any of its components, taking the medication again could result in severe allergic responses, such as skin rash, swelling, or difficulty breathing.

Pregnancy: Vorinostat is contraindicated during pregnancy because it can harm an unborn baby. For more details, refer to the Vorinostat in Pregnancy section.

Breastfeeding: Vorinostat can pass into breast milk and may pose risks to a nursing infant. For further information, see the Vorinostat while Breastfeeding section.

Drug-to-Drug Interactions with Vorinostat

Vorinostat has the potential to interact with other medications, which may increase the risk of side effects or reduce the effectiveness of one or both drugs. It is crucial to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, and dietary supplements. Below are some significant drug interactions associated with Vorinostat:

1. Warfarin (Coumadin): Combining Vorinostat with blood thinners like warfarin can elevate the risk of bleeding. Regular monitoring of blood clotting levels is strongly recommended.
2. Valproic acid (Depakote): Taking valproic acid alongside Vorinostat may increase the risk of low blood platelet counts, which can lead to excessive bleeding or easy bruising.
3. Romidepsin (Istodax): Both Vorinostat and romidepsin are histone deacetylase inhibitors used in cancer treatment. Using them together can intensify side effects, such as low blood cell counts or gastrointestinal discomfort.
4. Other HDAC inhibitors: Combining Vorinostat with other histone deacetylase inhibitors may amplify the risk of adverse effects, including reduced blood cell counts and digestive issues.

Vorinostat in Pregnancy

Is it safe to take Vorinostat during pregnancy?

No, Vorinostat is not considered safe during pregnancy. Studies have shown that this cancer medication can harm an unborn baby, potentially leading to birth defects or miscarriage. Women who are pregnant or planning to become pregnant should avoid using Vorinostat. Those of childbearing age must use reliable contraception during treatment and for at least six months after stopping the medication. If you become pregnant while taking Vorinostat, contact your healthcare provider immediately to discuss alternative treatment options.

Vorinostat while Breastfeeding

Is it safe to take Vorinostat while breastfeeding?

No, Vorinostat is not safe for use while breastfeeding. This medication can pass into breast milk and may pose serious risks to a nursing infant. If you are currently breastfeeding or planning to breastfeed, consult your healthcare provider to explore safer alternatives. You may need to discontinue breastfeeding or switch to a different medication to protect your child’s health.

Estimated Cost of Vorinostat Medication

The cost of a 30-day supply of Vorinostat without insurance can vary significantly depending on the pharmacy and location. With a GoodRx coupon, the estimated price typically falls between $10,000 and $12,000 for a 30-day supply. To obtain the most accurate pricing, it’s important to check directly with your pharmacy. Additionally, consider exploring discount programs or coupons, which may help reduce the cost.

Possible Alternatives to Vorinostat

If Vorinostat is not the most suitable option for your treatment, there are alternative therapies and lifestyle adjustments that may help manage your condition. Always consult your healthcare provider before making any changes to your treatment plan. If you’re seeking guidance, you can also schedule a telemedicine appointment with one of our providers to discuss these alternatives in detail.

Alternatives for Cutaneous T-Cell Lymphoma

For cutaneous T-cell lymphoma, other histone deacetylase inhibitors (HDAC inhibitors) such as romidepsin (Istodax) may be considered. Systemic therapies like methotrexate or interferon are also potential options. Additionally, phototherapy and topical steroids can be effective in certain cases.

Alternatives for Peripheral T-Cell Lymphoma

Treatment for peripheral T-cell lymphoma often involves chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). Targeted therapies, including brentuximab vedotin (Adcetris), may also be recommended based on the specific characteristics of the disease.

Alternatives for Hodgkin Lymphoma

Standard treatment options for Hodgkin lymphoma typically include chemotherapy regimens like ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiation therapy. Immunotherapy with drugs such as nivolumab (Opdivo) may also be an option, particularly for patients with relapsed or refractory disease.

Alternatives for Non-Hodgkin Lymphoma

For non-Hodgkin lymphoma, treatment options include chemotherapy, targeted therapies like rituximab (Rituxan), and radiation therapy. The choice of treatment depends on the specific subtype and stage of the disease.

Alternatives for Multiple Myeloma

In the case of multiple myeloma, alternatives include proteasome inhibitors such as bortezomib (Velcade), immunomodulatory drugs like lenalidomide (Revlimid), and stem cell transplantation. These treatments are often used in combination to achieve the best outcomes.

Alternatives for Acute Myeloid Leukemia

Standard therapies for acute myeloid leukemia include chemotherapy regimens such as cytarabine and daunorubicin. Targeted therapies like midostaurin (Rydapt) may also be incorporated into treatment plans, depending on the genetic profile of the leukemia.

Alternatives for Chronic Lymphocytic Leukemia

For chronic lymphocytic leukemia, targeted therapies such as ibrutinib (Imbruvica) or venetoclax (Venclexta) are commonly used. Chemotherapy may also be an option, depending on the patient’s overall health and disease characteristics.

Alternatives for Myelodysplastic Syndromes

Treatment for myelodysplastic syndromes often includes hypomethylating agents like azacitidine (Vidaza), growth factors to stimulate blood cell production, and blood transfusions to manage symptoms of anemia or low blood counts.

Alternatives for Solid Tumors

For solid tumors, treatment options vary widely depending on the type and stage of the tumor. Common approaches include surgery, radiation therapy, chemotherapy, and targeted therapies tailored to the specific cancer.

Alternatives for Lymphoproliferative Disorders

Treatment for lymphoproliferative disorders typically involves chemotherapy, immunotherapy, or targeted therapies. The choice of treatment depends on the specific type of disorder and its progression.

Recent Updates on Vorinostat Research

Recent research has focused on the use of Vorinostat in combination with other cancer therapies to improve outcomes for patients with various types of lymphoma and solid tumors. Ongoing clinical trials are also investigating its potential in treating other cancers, such as breast cancer and non-small cell lung cancer. Additionally, researchers are exploring Vorinostat’s ability to overcome resistance to other cancer treatments, which could make it a valuable component in combination therapies. As always, it’s essential to discuss any new or emerging treatment options with your healthcare provider. If you’re interested in learning more, you can schedule a telemedicine appointment with one of our providers to determine whether Vorinostat or other innovative therapies may be appropriate for your care.

James Kingsley

Learn More